Diffusion Pharmaceuticals (NASDAQ:DFFN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Diffusion Pharmaceuticals Stock Performance

Shares of DFFN opened at $5.80 on Thursday. The company has a market capitalization of $11.83 million, a P/E ratio of -0.76 and a beta of 1.82. Diffusion Pharmaceuticals has a one year low of $4.64 and a one year high of $19.80. The stock has a 50-day moving average price of $5.93 and a 200 day moving average price of $5.87.

Institutional Trading of Diffusion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Diffusion Pharmaceuticals during the first quarter valued at approximately $106,000. Trexquant Investment LP acquired a new stake in Diffusion Pharmaceuticals during the second quarter valued at approximately $71,000. Finally, Renaissance Technologies LLC raised its stake in Diffusion Pharmaceuticals by 8.3% during the first quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company’s stock valued at $331,000 after buying an additional 101,100 shares in the last quarter. Institutional investors and hedge funds own 9.24% of the company’s stock.

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals, Inc is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen. The firm’s product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.

Recommended Stories

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.